BFEC
IBRX icon

Benjamin F. Edwards & Company’s ImmunityBio IBRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$3K Sell
500
-200
-29% -$1.32K ﹤0.01% 1990
2024
Q1 		$4K Buy
700
+200
+40% +$906 ﹤0.01% 1916
2023
Q4 		$3K Hold
500
– – ﹤0.01% 1949
2023
Q3 		$1K Hold
500
– – ﹤0.01% 1712
2023
Q2 		$1K Hold
500
– – ﹤0.01% 1714
2023
Q1 		$1K Hold
500
– – ﹤0.01% 1727
2022
Q4 		$3K Buy
+500
New +$2.75K ﹤0.01% 1672

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Benjamin F. Edwards & Company's IBRX Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its ImmunityBio (IBRX) stake by 29% in Q2 2024, selling an estimated $1.32K and leaving 500 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Benjamin F. Edwards & Company first reported a position in IBRX in Q4 2022 and has held it in 7 quarters since. The position peaked at $4K in Q1 2024. 194 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

  • Benjamin F. Edwards & Company held 500 shares of ImmunityBio worth $3K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 200 ImmunityBio shares in Q2 2024, an estimated $1.32K.
  • ImmunityBio made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1990 holding.
  • Benjamin F. Edwards & Company first reported a position in ImmunityBio in Q4 2022 and has held it in 7 quarters since.
  • Benjamin F. Edwards & Company's ImmunityBio position peaked at $4K in Q1 2024.
  • 194 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.